“no one form the anti "proxy group" has addresse
Post# of 148165
How do you want it addressed?
We needed the money and thought we would have revenue soon enough to avoid the worst effects.
Unfortunately, CD10/12 didn’t give the results we needed, so we’re dealing with the consequences.
That’s life as a pre-revenue biotech.
Despite what The Group Formerly Known As 13D might try to pretend, there are no easy options. There are trade-offs with every alternative.
In any case, at the end of the day, the share price is still up 500% over the last two years.
So, claims about destruction of shareholder value ring *awfully* hollow to my ears.